A detailed history of Hsbc Holdings PLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 81,665 shares of STRO stock, worth $281,744. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,665
Previous 60,858 34.19%
Holding current value
$281,744
Previous $178,000 58.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.88 - $5.01 $59,924 - $104,243
20,807 Added 34.19%
81,665 $282,000
Q2 2024

Aug 12, 2024

BUY
$2.92 - $5.33 $15,779 - $28,803
5,404 Added 9.75%
60,858 $178,000
Q1 2024

May 15, 2024

BUY
$3.27 - $5.65 $9,989 - $17,260
3,055 Added 5.83%
55,454 $313,000
Q4 2023

Feb 12, 2024

BUY
$2.07 - $4.54 $50,979 - $111,811
24,628 Added 88.68%
52,399 $224,000
Q3 2023

Nov 13, 2023

BUY
$3.29 - $4.9 $91,366 - $136,077
27,771 New
27,771 $96,000
Q1 2023

May 15, 2023

BUY
$4.48 - $8.45 $6,504 - $12,269
1,452 Added 8.09%
19,410 $89,000
Q4 2022

Feb 14, 2023

BUY
$5.41 - $8.08 $20,687 - $30,897
3,824 Added 27.06%
17,958 $145,000
Q3 2022

Nov 14, 2022

BUY
$5.17 - $7.11 $8,153 - $11,212
1,577 Added 12.56%
14,134 $79,000
Q2 2022

Aug 11, 2022

BUY
$3.41 - $8.95 $42,819 - $112,385
12,557 New
12,557 $66,000
Q4 2020

Feb 12, 2021

SELL
$10.16 - $23.98 $164,012 - $387,109
-16,143 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$7.44 - $13.15 $120,103 - $212,280
16,143 New
16,143 $165,000
Q4 2019

Feb 14, 2020

SELL
$8.15 - $11.39 $146,374 - $204,564
-17,960 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$7.91 - $11.76 $142,063 - $211,209
17,960 New
17,960 $163,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $180M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.